Varicella-zoster virus (VZV) acute retinal necrosis and recombinant zoster vaccine

Rev Med Suisse. 2022 Apr 13;18(777):714-717. doi: 10.53738/REVMED.2022.18.777.714.ABSTRACTVaricella zoster virus (VZV) is responsible for chickenpox. Like all herpes viruses, after primary infection it enters into latency and can be reactivated afterwards. Many forms of symptomatic reactivation of VZV exist including acute retinal necrosis (ARN), an ophthalmic emergency which can lead to blindness. ARN is treated starting with high-dose intravenous acyclovir then with oral valaciclovir for a total duration of up to 3 months. Symptomatic reactivations of VZV are public health issues. The new Swiss 2022 vaccination plan includes the recombinant vaccine Shingrix. It effectively prevents VZV symptomatic reactivations even in elderly and immuno suppressed patients.PMID:35417100 | DOI:10.53738/REVMED.2022.18.777.714
Source: Herpes - Category: Infectious Diseases Authors: Source Type: research